Contact

Balveen Kaur, Core Director
614-292-3984
kaur.11@osu.edu

Nina Dmitrieva, Core Manager
614-292-1321
dmitrieva.1@osu.edu

Bringing together investigators studying glioblastoma biology and novel therapeutics to combat cancer.

This Core provides assistance to researchers studying brain tumor biology, offering centralized and standardized services for the preparation, characterization and injection of tumor cells into rodents in order to induce and model brain tumor formation. Services include tumor cell growth in vitro, tumor cell injection into rodents, animal monitoring, tumor volume measurements, tissue processing, and generation of brain slices. The Core also provides expert consultation on brain tumor projects.

The Xenograft Core is located in 385D Wiseman Hall. Core Director Balveen Kaur is available to discuss projects involving brain tumor implantation, testing therapeutics and following tumor growth and survival.

Services provided:

  • Tumor cell implantation in rodents: subcutaneous and orthotopic
  • Tumor volume measurements
  • Follow up of rodent survival
  • Euthanasia and tissue harvest

Please see our Terms of Service for specifics regarding use of this core.

Publications

Hardcastle J, Kurozumi K, Dmitrieva N, Sayers MP, Ahmad S, Waterman P, Weissleder R, Chiocca EA, Kaur B. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Molecular Therapy (2010) 18(2): 285-294. [PMCID: 2818668].

Dmitrieva N, Yu L, Viapiano M, Cripe TP, Chiocca EA, Glorioso JC, Kaur B. Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res. 2011 Mar 15;17(6):1362-72. doi: 10.1158/1078-0432.CCR-10-2213. Epub 2010 Dec 21. PubMed PMID: 21177410; PubMed Central PMCID: PMC3140790. 

Williams SP, Nowicki MO, Liu F, Press R, Godlewski J, Abdel-Rasoul M, Kaur B, Fernandez SA, Chiocca EA Lawler SE. Indirubins decrease glioma growth and invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Research (2011) 71(16):5374-80. PMID: 21697283.   

Yoo JY, Haseley A, Bratasz A, Chiocca EA, Zhang JY, Cain D, Powell K, Kaur, B. Antitumor Efficacy of 34.5ENVE: a transcriptionally retargeted and Vstat120 expressing oncolytic virus. Molecular Therapy (2012). 20(2):287-97. PMCID: PMC3277242. 

Alvarez-Breckenridge C, Yu J, Price R, Wei M, Wang Y, Nowicki P, Yoonhee M, Bergin S, Hwang C, Soledadad F, Kaur B, Caligiuri M, Chiocca EA. The HDAC inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells with inhibition of STAT5/T-BET signaling and generation of gamma interferon. Journal of Virology (2012) 86(8):4566-77. PMCID: PMC3318659

Haseley A, Boone S, Wojton J, Yu L, Yoo JY, Yu J, Kurozumi K, Glorioso J, Caligiuri M, Kaur B. Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Research, (2012) 72(6):1353-62. PMCID: PMC3366191 

Suh S, Yoo JY, Nuovo GJ, Jeon YJ, Kim S, Lee TJ, Kim T, Bakacs A, Alder H, Kaur B, Aqeilan RI, Pichiorri F, Croce CM. miR-25/32 restore p53 activity. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proceedings of the National Academy of Sciences USA. (2012). 09(14):5316-21. PMCID: PMC3325690

Yoo JY, Pradarelli J, Haseley A, Wojton J, Kaka A, Bratasz A, Alvarez-Breckenridge CA, Yu JG, Powell K, Mazar AP, Teknos TN, Chiocca EA, Glorioso JC, Old M, Kaur B. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV. Clin Cancer Res. 2012 Sep 15;18(18):4931-41. Epub 2012 Jul 2. PubMed PMID: 22753591; PubMed Central PMCID: PMC3784008.

Hu B, Nandhu MS, Sim H, Agudelo-Garcia PA, Saldivar JC, Dolan CE, Mora ME, Nuovo GJ, Cole SE, Viapiano MS. Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer Res. 2012 Aug 1;72(15):3873-85. 

Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, Vivier E, Mandelboim O, Moretta A, Caligiuri M, Chiocca EA. NK cells impede glioblastoma virotherapy via NKp30 and NKp46 natural cytotoxicity receptors. Nature Medicine (2012). 18(12):1827-34 PMCID: PMC3668784

Price RL, Song J, Bingmer K, Kim TH, Dr. Yi JY, Nowicki MO, Mo X, Hollon T, Murnan E, Alvarez-Breckenridge C, Fernandez S, Kaur B, Rivera A, Oglesbee M, Cook C, Kwon CH. Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Research, (2013) 73(11):3441-50. PMCID: PMC4136413

Wojton J, Chu Z, Mathsyaraja H, Meisen W, Denton N, Kwon CH, Chow LM, Palascak M, Franco R, Bourdeau T, Thornton S, Ostrowski M, Kaur B, and Qi X. “Systemic delivery of SapC-DOPS has anti-angiogenic and antitumor effects against glioblastoma” (2013) Mol Therapy. 21(8):1517-25. PMCID: PMC3734660

Gu C, Banasavadi-Siddegowda YK, Joshi K, Nakamura Y, Kurt H, Gupta S, Nakano I. Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. Stem Cells. 2013 May;31(5):870-81.

Racoma IO, Meisen WH, Kaur B, Snapka RM, Wani AW. Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells. Plos One (2013). 8(9):e72882

Okemoto K, Wagner B, Meisen H, Haseley A, Kaur B, Chiocca EA. STAT3 Activation Promotes Oncolytic HSV1 Replication in Glioma Cells. Plos One (2013). 8(8):e71932. doi: 10.137. PMCID: PMC3732216. 

Okemoto K, Kasai K, Wagner B, Haseley A, Meisen H, Bolyard C, Kaur B, Chiocca EA. DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas Clinical Cancer Research, (2013). 19(21):5952-9. PMCID: PMC3860592

Mao P, Joshi K, Li J, Kim SH, Li P, Santana-Santos L, Luthra S, Chandran UR, Benos PV, Smith L, Wang M, Hu B, Cheng SY, Sobol RW, Nakano I. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A. 2013 May 21;110(21):8644-9. doi: 10.1073/pnas.1221478110. Epub 2013 May 6. PubMed PMID: 23650391; PubMed Central PMCID: PMC3666732.

Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim SH, Mao P, Kig C, Nardini D, Sobol RW, Chow LM, Kornblum HI, Waclaw R, Beullens M, Nakano I. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells. 2013 Jun;31(6):1051-63.

Yan F, Alinari L, Lustberg M, Martin K, Cordero-Nieves, H, Banasavadi-Siddegowda, Y, Virk, S, Barnholtz-Sloan J, Hlavin Bell E, Wojton J, Jacob N, Chakravarti A, Nowicki O, Wu X, Lapalombella R, Datta J, Yu B, Gordon K, Haseley A, Patton JT, Smith P, Ryu J, Zhang X, Mo X, Marcucci G, Nuovo G, Kwon C, Byrd J, Chiocca EA, Li C, Sif A, Samson J, Lawler SE, Kaur B*, Baiocchi RA*. Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma. (2014) Cancer Res 15;74(6):1752-65. PMCID: PMC3959215. 

Yoo JY, Hurwitz B, Bolyard C, Yu J, Zhang J, Selvendiran K, Rath KS, He S, Bailey Z, Eaves D, Cripe T, Parris DS, Caligiuri MA, Old M, Kaur B. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic necroptic cell death Clinical Cancer Research (2014); 20(14):3787-98. PMCID: PMC4132885

Kim TH, Song J, Kim SH, Parikh AK, Mo X, Palanichamy K, Kaur B, Yu J, Yoon SO, Nakano I, Kwon CH. Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells. (2014). Neuro-Oncology. 16(10):1354-64. PMCID: PMC4165421.  

Thorne AH, Meisen WH, Russell L, Yoo JY, Bolyard CM, Lathia JD, Rich J, Puduvalli VK, Mao H, Yu J, Caligiuri MA, Tridandapani S, Kaur B. Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. Mol Ther. 2014 Sep;22(9):1678-87. doi: 10.1038/mt.2014.101. Epub2014 Jun 4. PubMed PMID: 24895995; PubMed Central PMCID: PMC4435480.

Wojton J, Meisen HM, Jacob N, Thorne A, Hardcastle J, Denton N, Chu Z, Dmitrieva N, Marsh R, Van Meir EG, Kwon CH, Chakravarti A, Qi X, Kaur B. SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma. (2014) Oncotarget. 5(20):9703-9. PMCID: PMC4259431

Van Brocklyn JR, Wojton J, Meisen WH, Kellough DA, Ecsedy JA, Kaur B, Lehman NL. Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma. (2014) (Cancer research) 74(19):5364-70. 

Ganguly R, Hong CS, Smith LG, Kornblum HI, Nakano I. Maternal embryonic leucine zipper kinase: key kinase for stem cell phenotype in glioma and other cancers. Mol Cancer Ther. 2014 Jun;13(6):1393-8

Meisen HW, Dubin S, Sizemore ST, Mathsyaraja H, Thies K, Lehman NL, Boyer P, Jaimie-Ramirez AC, Elder JB, Powell K, Chakravarti A, Ostrowski M, Kaur B. Changes in BAI1 and Nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies. (2015) Molecular Cancer Therapeutics 14(1):307-14. PMCID: PMC4297221

Mazzacurati L, Marzilli M, Reinhart B, Miyagawa Y, Uchida H, Goins WF, Li A, Kaur B, Caligiuri M, Cripe T, Chiocca EA, Amankulor N, Cohen JB, Glorioso JC, Grandi P. Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV. (2015) Molecular Therapy. 23(1):99-107. PMCID: PMC4426800

Lee TJ, Haque F, Shu D, Yoo JY, Li H, Yokel RA, Horbinski C, Kim TH, Kim SH, Kwon CH, Nakano I, Kaur B, Guo P, Croce CM. RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model. (2015) Oncotarget. 20;6(17):14766-76.

Meisen HW , Wohleb ES, Jaime-Ramirez CA, Bolyard CM, Yoo JY, Russell L, Hardcastle J, Dubin S, Muili K, Yu J, Caligiuri MA, Godbout J, Kaur B. The impact of macrophage and microglia secreted TNFα on oncolytic HSV-1 therapy in the glioblastoma tumor microenvironment. (2015) Clinical Cancer research 15; 21(14):3274-85.

Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P, Wang QE, He X, Nakano I, Chiocca EA, Glorioso JC, Kaur B, Caligiuri MA, Yu J. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. (2015) Sci Rep. Jul 9; 5:11483. doi: 10.1038/srep11483. PMCID: PMC4496728.

Cheng C, Ru P, Geng F, Liu J, Wu X, Cheng X, Euthine V, Hu P, Guo JY, Lefai E, Kaur B, Nohturfft A, Ma J, Chakravarti A, Guo D. Glucose-mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth. (2015) Cancer Cell. 28(5):569-81.

Kim SH, Joshi K, Ezhilarasan R, Myers TR, Siu J, Gu C, Nakano-Okuno M, Taylor D, Minata M, Sulman EP, Lee J, Bhat KP, Salcini AE, Nakano I. EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner. Stem Cell Reports. 2015 Feb 10;4(2):226-38.

Share this Page